aprocitentan · Idorsia · NDA 217686
Tryvio
Earliest generic entry, as listed
26 Jul 2038
Blocked by patent: US 11680058. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11680058 | use U-3878 | 26 Jul 2038 |
| US 11787782 | use U-3877 | 2 Mar 2038 |
| US 10919881 | substance, product | 26 Feb 2038 |
| US 12297189 | product | 26 Feb 2038 |
| US 11174247 | use U-3879 | 6 Nov 2037 |
| US 8324232 | substance, product, use U-3878 | 21 Sep 2029 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 22 Mar 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217686 · 001 · RLD | tablet, oral | 12.5MG | 26 Jul 2038 |